Delhi High Court Orders Review Of Indian Decision Against Ranbaxy Drug Price
This article was originally published in PharmAsia News
India's Delhi High Court has ordered the government to reconsider a decision fixing the price of Ranbaxy's antibiotic Roscillin (ampicillin sodium). The National Pharmaceutical Pricing Authority had declined to review its decision, saying Ranbaxy must first bring its price for the drug into line, and then file for a review. The court ordered the Ministry of Chemicals and Fertilizers to consider the Ranbaxy request within four weeks. The ultimate decision is expected to have the force of a judicial ruling. (Click here for more
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.